Drugs / JNJ-1761981
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07525141 | May 2026 → Jan 2028 expected | neoplasm | Johnson & Johnson Enterprise Innovation Inc. | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | JNJ-1761981 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07525141 ↗ |
| Route | Other | “JNJ-1761981 will be administered intratumorally.” NCT07525141 ↗ |